How rethinking risk management can drive trust, innovation & growth
The medical device sector stands at a crossroads, confronting regulatory evolution, supply chain fragility, complex technical and scientific development, cyber threats, and evolving patient demands. This Viewpoint explores resilience as a strategic imperative — essential for patient safety, operational continuity, and sustained competitive advantage. By leveraging predictive risk management, medical device companies can turn proactive resilience into enhanced patient outcomes and robust corporate performance.
The medical device industry is undergoing significant transformation, driven by converging technologies, tightening regulations, rising patient expectations, and complex hardware-software-drug combinations. Yet, viewing resilience through the narrow lens of compliance, which overlooks broader opportunities, still dominates the industry.
Across industries, leading organizations now recognize resilience as more than a defensive tool; they consider it a strategic asset that delivers competitive advantages and improves patient outcomes. In this context, resilience is no longer characterized by a reactive mindset. It extends beyond disruption avoidance to reflect a company’s ability to anticipate, absorb, adapt to, and recover from shocks from supply chain vulnerabilities, cyber threats, regulatory changes, or global crises. Leaders in the medical device industry increasingly see that resilient businesses outperform competitors because they maintain operations, adapt quickly, and retain patient trust, even under pressure. They measure their success through KPIs that clearly indicate resilience maturity, including recovery time objectives (RTOs), fulfillment rates during disruption, and patient satisfaction.
Building resilience into corporate strategy enables medical device firms to protect patient care and unlock growth through agility and innovation. These companies gain the confidence of patients, providers, regulators, and investors, which strengthens market positioning and long-term value. They can pivot swiftly in response to regulatory shifts, maintain production through supply chain shocks, and recover rapidly from cyber incidents, which generates market share and loyalty.
Resilience can no longer focus solely on avoiding risk. The industry must reframe it as a performance enabler. Responsibility for resilience must extend beyond compliance teams and become embedded across all functions: supply chain, quality, regulatory, R&D, manufacturing, technology, commercial, and executive leadership.
What role do patients play? By recognizing resilience as a strategic advantage, medical device companies can reorient their approach around the industry’s primary stakeholder: the patient. Resilience must encompass uninterrupted supply, reliable performance under varied conditions, and proactive communication during periods of uncertainty.
Traditionally, patient interests tend to rely on the perspective of safety, quality, and efficacy. While these qualities remain critical, today’s environment demands a broader, more holistic understanding of resilience, with a much broader focus on patients. As devices become more accessible, patients increasingly expect and depend upon the uninterrupted availability and reliability of devices vital to their quality of life, placing resilience at the heart of trust and corporate responsibility. For them, resilience translates to dependable access to essential medical devices, such as dialysis machines, cardiac monitors, and glucose management systems. Their expectations place resilience at the heart of trust and corporate responsibility.
For patients dependent on ventilators or insulin-delivery systems, even brief disruptions can have severe consequences, reinforcing the need for resilience across supply chains and operations. This factor introduces an ethical imperative unique to the medical device industry: disruptions affect lives, magnifying moral responsibilities alongside commercial ones. Reliability isn’t a bonus; it’s foundational to confidence in care.
Moreover, patient trust, critical yet fragile, can erode quickly during uncertainty. This element also hinges on accurate, clear data, especially in home-care settings, where patients must make independent decisions. Patient expectations and standards have increased, and they expect full transparency when disruptions occur. Timely, patient-friendly updates via websites or social media can ease anxiety, manage expectations, and reinforce trust, making communication itself a vital aspect of resilience.
Medical device companies can significantly strengthen their risk management with patient-centered resilience, building on traditional approaches while embedding ethical imperatives, such as consistent device availability, adaptive risk management, and transparent communication (see Figure 1). The result: stronger trust, better patient outcomes, and leadership in redefining industry standards.
Recognizing patients as central stakeholders demands that medical device companies understand the strategic forces driving the need for operational resilience. While resilience safeguards patient outcomes, it also supports strategic goals, such as innovation, market growth, and reputation management. Several drivers stand out:
Ultimately, strategic resilience in the medical device industry helps companies stay ahead by anticipating challenges, adapting quickly, and consistently meeting patient needs. Companies that build resilience into their business plans can effectively handle unexpected disruptions, maintain patient trust, drive innovation faster, and strengthen their position in the market.
Medical device companies must embed strategic resilience practices across the value chain to witness the full operational impact. This requires tailored approaches to risk management and business continuity that reflect the sector’s unique demands. Applying specifically adapted methodologies, such as business impact analysis (BIA) and strategic continuity planning, aligned with recognized international standards like ISO 22301 (business continuity management) and ISO 31000 (risk management) are key to this integration. The structured resilience process, which spans prediction, prevention, preparedness, response, and recovery, is illustrated in the Arthur D. Little (ADL) Integrated Patient-Centric Resilience Framework (see Figure 2).
A BIA, designed specifically for medical device operations, forms the core of this integration. Unlike traditional BIAs, which focus mainly on financial or operational losses, a medical device–specific BIA prioritizes patient outcomes and clinical continuity. It analyzes activities critical to the uninterrupted supply of life-saving devices, identifies single-source dependencies (e.g., specialized microchips or biocompatible polymers), and evaluates geographic risks (e.g., manufacturing hubs in politically unstable or disaster-prone regions).
For instance, conducting a BIA of a cardiac device manufacturer may reveal that obtaining key components from a single region introduces significant risks to patient safety and supply continuity. In such cases, the BIA measures implications for patient health outcomes and regulatory compliance, in addition to financial impact. Aligning outputs to patient-critical factors clarifies which activities require protection, enabling targeted mitigation and resource allocation.
These insights are then used to develop a continuity plan specific to the medical device value chain. Rather than applying generic risk approaches, this plan should include detailed, practical interventions, such as diversifying the sources of key components and establishing secondary manufacturing or assembly sites that could rapidly scale during disruption. This process might involve pre-qualifying alternate suppliers, investing in geographically distributed production capacity, or forming reciprocal agreements with peers. One major diagnostics manufacturer, for example, maintained 96% fulfillment rates during global transport slowdowns by establishing regional warehousing and adding redundant packaging lines in Eastern Europe.
An effective continuity strategy also relies on clearly defined incident management frameworks tailored to regulated environments. For example, the ISO 22301 standard specifies roles, escalation procedures, and protocols to ensure regulatory compliance during disruptions. Within the medical device sector, effective incident management involves prompt reporting of adverse events or product issues directly to relevant authorities such as the FDA or EMA (European Medicines Agency), rapid communication with healthcare providers and affected patients, and structured recovery processes that swiftly restore both regulatory compliance and public trust. To strengthen readiness, several global medtech companies now conduct annual mock audits and crisis-response simulations involving regulatory bodies, enabling teams across quality assurance, regulatory affairs, manufacturing, and communications to practice coordinated responses under realistic conditions.
To implement continuity strategies effectively, companies must also adopt clear, actionable resilience metrics aligned with patient-focused goals. Two key measures are RTOs, the maximum acceptable time to resume critical manufacturing, and maximum tolerable periods of disruption (MTPDs), beyond which patient safety is jeopardized. For example, RTOs for a life-critical ventilator may be measured in hours, while longer RTOs might be acceptable for noncritical devices with available substitutes, which allows for strategic prioritization.
Ultimately, using tailored strategies to embed resilience in the value chain ensures regulatory compliance and aligns with patient safety and continuity. Companies become more agile, responsive, and resilient as they progress along the resilience maturity scale (see Figure 3), from reactive to adaptive, with predictive models using AI and analytics. By working resilience into the fabric of operations, medical device firms position themselves to not just withstand disruption, but to emerge stronger, more patient-focused, and competitively advantaged.
Medical device companies now have a powerful strategic lever as they build robust operational resilience frameworks: digital transformation. By harnessing digital capabilities, predictive analytics, the Internet of Things (IoT), AI-driven visibility, and real-time regulatory intelligence, organizations can anticipate disruptions, enhance agility, and significantly reinforce resilience.
Predictive analytics and IoT technologies offer transformative potential for proactive resilience management. Medical device manufacturers often rely on specialized equipment, such as precision molding machines or sterilization chambers, where failures can halt production and disrupt patient supply. IoT sensors and predictive analytics can monitor production in real time, enabling targeted maintenance and reducing downtime. A leading cardiovascular implant manufacturer, for example, deployed IoT sensors in its cleanroom production environment and reduced unscheduled downtime through forward-looking interventions.
Digitalization also brings unprecedented transparency and responsiveness to complex supply chains. AI-driven visibility platforms provide continuous real-time risk assessment, identifying supplier instability, geopolitical disruptions, or single-source dependencies. One global diagnostics manufacturer used AI-powered digital twins to navigate COVID-19 challenges, rapidly sourcing alternatives and rerouting logistics to maintain supply continuity.
Digital tools also strengthen compliance in an evolving regulatory landscape. Real-time regulatory intelligence systems aggregate and analyze data across jurisdictions so companies to stay informed and responsive. Predictive alerts and scenario planning have helped manufacturers adjust operations and documentation to align with EU MDR and FDA cybersecurity updates. Cybersecurity will become even more critical as digital health solutions expand. AI-driven security tools support proactive threat detection and mitigation. For instance, a diabetes-care manufacturer applied machine learning to enhance protections around its connected insulin-delivery systems, safeguarding both data and patient safety.
Digital transformation has expanded beyond modernizing operations; it’s evolved into a vital enabler of strategic resilience. Medical device companies can strengthen their resilience, safeguard patient outcomes, and secure a lasting competitive edge by embedding digital capabilities across manufacturing, supply chains, compliance, and cybersecurity.
Case study: Supply chain failure of a critical-care anticoagulant
In 2019, a major US pharmaceutical supplier experienced a severe disruption to its production of a life-saving anticoagulant used extensively in cardiovascular surgery and dialysis treatments. The drug, derived from animal-based raw materials, was affected by an outbreak of disease, which devastated livestock populations in the supplier’s sole sourcing region. The product’s central role in critical care caused the disruption to escalate quickly into a public health emergency, attracting regulatory scrutiny and government intervention. Although the manufacturer ensured the product remained safe, effective, and compliant with regulatory standards, its dependence on a single-source supply chain exposed patients, healthcare providers, and public agencies to significant operational risks.
The shortage led to delayed procedures, compromised care, and reduced confidence in the manufacturer’s ability to ensure continuity, resulting in reputational damage and heightened regulatory pressure. Had the company used diversified sourcing or geographically distinct secondary suppliers to strengthen its supply chain, the impact could have been mitigated and the disruption turned into an example of operational foresight and leadership. Instead, the incident underscored the critical importance of integrating resilience into medical product manufacturing to protect patient welfare and ensure continuity of care in the face of global challenges.
Existing risk management approaches must evolve to meet the future needs of medical device stakeholders. The sector faces intensifying demands from multiple directions. Reframing resilience through the standpoint of patient impact is not optional; it is a strategic necessity, enabling companies to respond more effectively, outperform competitors, and create long-term value. The benefits are clear:
Together, these outcomes position resilience to drive sustainable growth, operational excellence, and stronger relationships with regulators, investors, and patients. It is time for leadership teams to elevate resilience in the strategic agenda and embed it as a core enabler of future performance.
By Jacob Power, Dominic Thompson, David Boulton, Beatrice De Marchi, Koen Segers, Tom Teixeira
cloud technology axon
Headquartered in France with an established footprint across the Unite...
